Clinical Research Directory

Inclusion Criteria: * Age ≥ 18 and \< 66 years * Patient with acute myeloid leukemia (AML) high risk in 1st complete remission: * CR1 obtained by 2 cycles of chemotherapy, * unfavorable Cytogenetics * FLT3 Duplication, * Or acute myeloid leukemia (AML) in 2nd complete remission, * Or acute lymphoblastic leukemia (ALL) High-risk 1st complete remission: * Presence of the translocation t (9; 22), * Or acute lymphoblastic leukemia (ALL) in 2nd complete remission, * Or Chronic Myeloid Leukemia (LCM) beyond the 1st chronic phase * Or Myelodysplasia or with IPSS score with 2 or more * Or Hodgkin's disease in sensitive relapse or beyond the 2nd complete remission. or following types of lymphoma : * Diffuse large B lymphoma cells relapsed or refractory after two lines of treatment or after a line with autologous hematopoietic stem cell, or * Mantle cell lymphoma relapsed or refractory after two lines of treatment or after a line with autologous hematopoietic stem cell * Others aggressive lymphoma for which an indication of allograft is selected (Burkitt lymphoma, lymphoblastic lymphoma, intravascular lymphoma, ...) * Lymphoma (low-grade follicular lymphoma, marginal zone lymphoma) in histological transformation. * Low-grade lymphoma for which an indication of allograft is retained * Unable to receive myeloablative conditioning because of age (\> 45 years) and/or the existence of co-morbidities precluding a myeloablative conditioning (status ECOG \> / = 2, DLCO \<50%, fungal infection proven or probable in the previous 60 days) and / or prior treatment with total body irradiation at doses above 2 Gy or busulfan doses\> 8 mg/kg * No contra-indication for a transplant in allogeneic non-myeloablative conditioning, * No HLA-identical sibling, * Absence of an unrelated donor on national or international registering with a 10/10 allelic matching or a 9/10 allelic matching with the only tolerated mismatches being: HLA-C. * No unit of placental blood available fulfilling the characteristics of compatibility (HLA compatible at least 4/6 allele or generic) and richness * Provision of at least 2 units of placental blood, whose compatibility is 4/6, 5/6 or 6/6 and whose richness is before thawing, \> 2 x 107 and \< 3 to 4 x 107 nucleated cells per/kg. * Patient affiliated to a social security scheme, * Free and informed consent signed by the patient and the investigator. Exclusion Criteria: * Age \<18 and ≥ 66 years * Malignant myeloid or lymphoid acute or chronic disease without indication for an allogeneic transplant according to the criteria of European Bone Marrow Transplantation Group. * Able to receive a myeloablative conditioning because of age (\<45 years) and the absence of co morbidities (status ECOG\> / = 2, DLCO \<50%, fungal infection proven or probable in 60 preceding days) and the absence of prior treatment with total body irradiation at doses above 2 Gy or busulfan doses\> 8 mg / kg * Contra indication for a non-myeloablative conditioning, * HLA-identical sibling available * Availability of an unrelated donor on a national or international register with 10/10 or 9/10 HLA matching (HLA-C Mismatch tolerated). * At least one unit of cord blood available with the characteristics of compatibility (HLA compatible at least 4/6 allelic or generic) and richness (before thawing\> / = 3 to 4 x 107 nucleated cells/kg recipient, by degree of compatibility) * Absence of at least 2 units of placental blood, whose compatibility is 4/6, 5/6 / or 6/6 and whose richness before thawing is \> 2 x 107 and \< 4 x 107 nucleated cells per/kg of recipient. * Women of childbearing age not using contraception, pregnant or lactating